Involvement of purinergic signaling in cardiovascular diseases.
Purine receptor subtypes are expressed with some selectivity on different types of cells in the cardiovascular system and are possible targets for therapeutic strategies in cardiovascular diseases. The considerable efforts of the clinical biochemists working in this field is leading to a promising emergence of subtype-specific P2 ligands. This will open up new avenues for research into the physiological roles of purine receptors and their therapeutic potential.
Ralevic
Vera
V
School of Biomedical Sciences, University of Nottingham Medical School, Queen's Medical Centre, United Kingdom. g.burnstock@ucl.ac.uk
Burnstock
Geoffrey
G
D000818:Animals; D002317:Cardiovascular Agents / Q000494:pharmacology / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000378:metabolism*; D002319:Cardiovascular System / Q000166:cytology / Q000378:metabolism*; D015195:Drug Design; D006801:Humans; D009708:Nucleotidases / Q000378:metabolism; D058906:Purinergic P1 Receptor Agonists; D058915:Purinergic P1 Receptor Antagonists; D058910:Purinergic P2 Receptor Agonists; D058919:Purinergic P2 Receptor Antagonists; D011687:Purines / Q000378:metabolism; D011743:Pyrimidines / Q000378:metabolism; D018047:Receptors, Purinergic P1 / Q000502:physiology*; D018048:Receptors, Purinergic P2 / Q000502:physiology*; D015398:Signal Transduction
D002317:Cardiovascular Agents; D058906:Purinergic P1 Receptor Agonists; D058915:Purinergic P1 Receptor Antagonists; D058910:Purinergic P2 Receptor Agonists; D058919:Purinergic P2 Receptor Antagonists; D011687:Purines; D011743:Pyrimidines; D018047:Receptors, Purinergic P1; D018048:Receptors, Purinergic P2; D009708:Nucleotidases